International Journal of Obesity最新文献

Long wait times, limited resources, and a lack of local options mean that many people with severe obesity cannot access treatment. Face-to-face group-based interventions have been found effective and can treat multiple people simultaneously, but are limited by service capacity. Digital group interventions could reduce wait times, but research on their effectiveness is limited. This systematic review aimed to examine the literature about online group-based interventions for adults with severe obesity (BMI ≥ 35 kg/m²). The review followed the PRISMA and PICOS frameworks. MEDLINE, Embase, CINAHL, Web of Science, and Cochrane Central Register of Controlled Trials were searched. Two authors independently screened articles. Data extraction, analysis, and quality assessment (using RoB2 and MMAT) was shared between two authors. A meta-analysis was conducted on eligible studies; other results were descriptively analysed. 20 papers reporting on 15 studies were included. Most studies reported some evidence of weight loss, but evidence of weight-related behaviour change was mixed. A meta-analysis on four studies indicated that online, group-based interventions had a statistically significant impact on weight loss (p = 0.001; 95% CI -0.69 to -0.17) with a small-to-moderate effect size, compared to waitlist or standard care conditions. Online interventions were considered more convenient but lack of familiarity with the group or counsellor, accessibility issues, and time constraints hindered engagement. Technical support, incentives, and interactive forums to improve group cohesion could mitigate these barriers. The findings suggested that online, group-based interventions are feasible and potentially beneficial, but barriers such as internet accessibility, digital literacy, and unfamiliarity with group members need to be mitigated. Key recommendations to improve experience and impact include providing instructions and run-throughs, building group cohesion, and providing session and additional content throughout the intervention. Future studies should focus on the influence of specific intervention characteristics and investigate the effect of these interventions compared to face-to-face interventions. Registration: National Institute for Health Research, PROSPERO CRD42021227101; https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021227101 .

Background/objectives: A high level of visceral fat area (VFA) is associated with obesity and cardiometabolic risk factors. VFA measured by computer tomography (CT) scan is accurate but has limitations for everyday use. Meanwhile, near-infrared (NIR) light penetrates the superficial layers of the human body so that fat content can be measured just as CT imaging measures fat accumulation.

Subjects/methods: This study evaluated whether discrete multi-wavelength NIR spectroscopy (DMW-NIRS) can be used to measure abdominal fat as a satisfactory alternative to a CT scan. 290 subjects were enrolled in this study, and each subject underwent DMW-NIRS NIR measurement and CT scan. A sex-specific DMW-NIRS-based VFA estimation formula was developed by multiple linear regression, including lipid density, age, and body mass index (BMI).

Results: The model of DMW-NIRS estimated VFA gave the least Akaike Information Criterions (AIC), Root Mean Squared Errors (RMSE), and the greatest Coefficient of determination (R²) to predict VFA (1199, 29.5, 0.544 in female, and 1714, 41.3, 0.504 in male, respectively). Also, the DMW-NIRS estimated that VFA was highly performed to determine visceral obesity, which is comparable with other obesity surrogates.

Conclusions: This study suggested that lipid density can be used as a valid, noninvasive method to determine visceral obesity.

Background: Sixty minutes is currently the shortest testing duration for 24-h resting energy expenditure (24-h REE) utilizing whole-room indirect calorimetry.

Objective: Show that recalculated 30-min extrapolated 24-h REE from previously published 60-min metabolic data are valid.

Methods: Propane consumption linearity was determined through an 8-h combustion test. Thereafter, metabolic data for 24-h extrapolated ventilation rates of oxygen (VO₂; l/d), carbon dioxide (VCO₂; l/d), respiratory quotient (RQ; VCO₂/VO₂), and REE (MJ/d) from ten 60-min propane combustion tests were recalculated to reflect a 30-min testing duration. A similar analysis was performed utilizing data from 60-min subject metabolic measurements within a whole-room indirect calorimeter (4597 liters) specific for measuring resting energy expenditure (REE). Statistical (p < 0.05) comparisons between recalculated and original 60-min metabolic data were determined by SPSS (version 29).

Results: Propane consumption during a combustion test was found to be linear for up to 8-h. Furthermore, no differences existed between propane stoichiometry and combustion for any of the extrapolated 24-h metabolic parameters when recalculated from 60-min propane combustion data to reflect a 30-min duration. Finally, similar results were obtained for all recalculated subject metabolic data.

Conclusions: Recalculated extrapolated 24-h metabolic data derived from a 30-min testing duration appear to be valid. This suggests that whole-room indirect calorimetry could be an adjunct for various weight loss or other programs where accurate metabolic measurements are required.

Overweight and obesity in children and adolescents may impact pharmacokinetics and drug exposure. The aim of the present study was to evaluate doses of antidepressants in relation to body weight in children. We used data from the BMI Epidemiology Study (BEST) Gothenburg cohort and the National Prescribed Drug Register and included children and adolescents with a prescription of fluoxetine (n = 347) or sertraline (n = 733) and a weight measurement. For fluoxetine, individuals with overweight or obesity received slightly lower doses at first prescriptions, but not in iterated prescriptions. The weight-normalized dose was lower in individuals with overweight or obesity in first and iterated prescriptions, compared with normal weight (p < 0.01). For sertraline, there were no significant dose differences between individuals with overweight or obesity, compared with normal weight. However, pronounced differences were seen in dose per kilogram body weight in both first and iterated prescriptions (p < 0.01). We conclude that the doses of fluoxetine and sertraline were essentially similar in individuals with overweight or obesity, but the weight-normalized doses were clearly lower. Given the ongoing obesity epidemic, larger studies addressing optimal dosing in individuals with elevated weight are warranted.

Background: There is a lack of clarity on the comparative effects of different beverages on weight loss in adults.

Objective: This study aimed at quantifying and ranking the effects of different beverages on weight loss.

Methods: We searched PubMed, Scopus, and Web of Science up to January 2023. We included randomized trials evaluating the comparative effects of two or more beverages, or compared a beverage against a control group (water, no intervention), for weight loss in adults. We conducted a random-effects network meta-analysis (NMA) with a Bayesian framework to estimate mean difference [MD] and 95% credible interval [CrI].

Results: In total, 78 randomized trials with 4168 participants were eligible. Low/no-calorie sweetened beverages (LNCSB) was effective for weight loss compared with water (MD: -0.79 kg, 95% CrI: -1.35, -0.18), milk (MD: -0.80 kg, 95% CrI: -1.59, -0.01), fruit juice (MD: -0.83 kg, 95% CrI: -1.47, -0.13), sugar-sweetened beverages (SSB) (MD: -1.08 kg, 95% CrI: -1.65, -0.50), and no intervention (MD: -1.19 kg, 95% CrI: -1.93, -0.41). However, in sensitivity analyses, no significant effect was seen in trials with a low risk of bias and those that implemented calorie restriction. LNCSB drinking was effective for waist circumference reduction compared with water (MD: -1.85 cm, 95% CrI: -3.47, -0.22). The certainty of evidence from most comparisons was rated low.

Conclusions: This study suggested evidence of low certainty that intake of LNCSBs can result in a small weight loss when used as a substitute for other beverages. Considering the low certainty of evidence, more research is needed to compare the effects of different beverages on body weight.

Trial registration: Not applicable, but the protocol of this systematic review was registered at PROSPERO (registration number: CRD42023407937).

Background: Retinoic acid (RA) participates in weight regulation and energy metabolism. Mice lacking ALDH1A1, one of the major enzymes responsible for RA biosynthesis, are resistant to diet-induced obesity. Previously, we identified FSI-TN42 (N42) as an ALDH1A1-specific inhibitor and reported its pharmacokinetics and pharmacodynamics as well as its efficacy in weight suppression.

Methods: In the first study, C57BL/6 J male mice were fed a high fat diet for 8 weeks to induce obesity. Mice were then divided into three groups and fed (1) moderate fat diet (MFD), (2) MFD + WIN 18,446 (1 g/kg diet), or (3) MFD + N42 (1 g/kg diet) for 8 weeks. A control group of mice were fed a low-fat diet for the entire period. Mice were weighed weekly and fasting glucose was determined every 4 weeks. Tissues were examined for potential toxicity using histopathology and complete blood counts. In the second study, we examined influences of N42 on energy balance and/or appetite by determining food intake, activity and energy expenditure in mice with obesity treated with MFD or MFD + N42. Lastly, we tested fertility with a mating study.

Results: N42 significantly accelerated weight loss compared to MFD alone in mice with obesity by reducing fat mass without decreasing lean mass. N42 did not alter food intake or activity levels. While mice treated with N42 lost significantly more weight, they maintained a similar level of energy expenditure compared to mice fed MFD only. Mice fed N42 preferentially used fat postprandially, especially under thermoneutral or mild cold challenge. N42 did not affect male fertility.

Conclusions: N42 promotes weight loss when used with MFD in mice with diet-induced obesity without causing significant organ toxicity or male infertility. Future studies will determine if N42 can be used to promote further weight loss if combined with current weight loss drugs.